Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,884,151 papers from all fields of science
Search
Sign In
Create Free Account
XR9576
Known as:
XR 9576
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
tariquidar
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET
K. Kawamura
,
F. Konno
,
+8 authors
Ming-Rong Zhang
Annals of Nuclear Medicine
2010
Corpus ID: 23029831
ObjectiveXR9576 (tariquidar) is an anthranilic acid derivative and potent P-glycoprotein (P-gp) inhibitor. XR9576 has undergone…
Expand
2010
2010
Abstract 3527: A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer
R. Kelly
,
R. Robey
,
+8 authors
S. Bates
2010
Corpus ID: 72138390
Purpose: P-glycoprotein (Pgp) antagonists have been difficult to develop because of complex pharmacokinetic interactions and a…
Expand
Highly Cited
2010
Highly Cited
2010
Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.
Jin-Oh Kwak
,
Sung Hee Lee
,
+6 authors
Min Goo Lee
European Journal of Pharmacology
2010
Corpus ID: 3040524
2006
2006
In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
P. Labrie
,
Shawn P. Maddaford
,
+4 authors
R. Gaudreault
Bioorganic & Medicinal Chemistry
2006
Corpus ID: 8982000
2005
2005
The coupling mechanism of P‐glycoprotein involves residue L339 in the sixth membrane spanning segment
A. Rothnie
,
J. Storm
,
R. McMahon
,
Andrewf . Taylor
,
I. Kerr
,
R. Callaghan
FEBS Letters
2005
Corpus ID: 34032519
2005
2005
Tariquidar (XR9576) is a potent and effective P-glycoprotein (Pgp) inhibitor that can be administered safely with chemotherapy
M. Menefee
,
C. Fan
,
+7 authors
A. Fojo
2005
Corpus ID: 58965144
3093 Background: Inhibition of P-glycoprotein (Pgp) as a means to improve chemotherapeutic efficacy remains a valid but unproven…
Expand
Highly Cited
2003
Highly Cited
2003
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
M. Agrawal
,
J. Abraham
,
+5 authors
Clara C. Chen
Clinical Cancer Research
2003
Corpus ID: 32285021
99mTc-sestamibi, a substrate of the multidrug transporter P-glycoprotein (Pgp), has been used as a functional imaging agent for…
Expand
2003
2003
Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles.
S. Köhler
,
W. Stein
Biotechnology and Bioengineering
2003
Corpus ID: 31361130
The appearance of multidrug resistance (MDR) of cancer cells is a major obstacle to successful chemotherapy. Several proteins…
Expand
2003
2003
Increased 99 mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor , XR 9576
M. Agrawal
,
J. Abraham
,
+5 authors
Clara C. Chen
2003
Corpus ID: 29455011
Tc-sestamibi, a substrate of the multidrug transporter P-glycoprotein (Pgp), has been used as a functional imaging agent for the…
Expand
2001
2001
In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator , XR 9576
2001
Corpus ID: 21453389
The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells causes multidrug resistance (MDR). This protein acts as…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE